Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

10645	Companies
226412	Keywords
154874	Articles
119836	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 04/16/2024 at 14:30, 2 years 2 months ago

Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Jaguar Health, Inc. announces commercial launch in Q3 2024 for Gelclair® for cancer supportive care. Gelclair is an FDA-approved oral mucositis prescription product for pain management in oncology

Jaguar Health Inc. Commercial Launch Gelclair Oral Mucositis Prescription Product
BRIEF

published on 04/09/2024 at 22:20, 2 years 2 months ago

Jaguar Health Reports Successful Stockholder Meeting and Progress on Clinical Trial

Jaguar Health Nasdaq Compliance Cancer Therapy Stockholder Meeting Crofelemer Clinical Trial
BRIEF

published on 04/09/2024 at 22:20, 2 years 2 months ago

Jaguar Health annonce une assemblée d’actionnaires réussie et des progrès dans les essais cliniques

Assemblée Générale Santé Jaguar Thérapie Contre Le Cancer Conformité Au Nasdaq Essai Clinique Crofelemer
PRESS RELEASE

published on 04/09/2024 at 22:15, 2 years 2 months ago

Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
Jaguar Health, Inc. announces decision not to implement a reverse split at this time. Top line results for phase 3 OnTarget trial of crofelemer pending. Stockholders approve proposals at Special Meeting

Crofelemer Stockholders Meeting Jaguar Health Reverse Split Phase 3 Trial
BRIEF

published on 04/08/2024 at 14:35, 2 years 2 months ago

Jaguar Health Granted Extension to Regain Nasdaq Compliance, Announces OnTarget Trial Results Soon

Crofelemer Jaguar Health Nasdaq Compliance Cancer Therapy OnTarget Trial
BRIEF

published on 04/08/2024 at 14:35, 2 years 2 months ago

Jaguar Health obtient une prolongation pour rétablir la conformité au Nasdaq et annonce bientôt les résultats de l'essai OnTarget

Crofelemer Santé Jaguar Thérapie Contre Le Cancer Conformité Au Nasdaq Essai OnTarget
PRESS RELEASE

published on 04/08/2024 at 14:30, 2 years 2 months ago

Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
Jaguar Health, Inc. announces extended grace period from Nasdaq for bid price compliance. Top line results awaited for crofelemer's cancer therapy-related diarrhea prevention trial

Crofelemer Nasdaq Jaguar Health Cancer Therapy Grace Period
BRIEF

published on 04/02/2024 at 14:35, 2 years 2 months ago

Jaguar Health, Inc. Announces Appointment of European Pharmaceutical Industry Veteran as President of Jaguar International

Pharmaceutical Industry Crofelemer Jaguar Health Massimo Radaelli Commercial Expansion
BRIEF

published on 04/02/2024 at 14:35, 2 years 2 months ago

Jaguar Health, Inc. annonce la nomination d'un vétéran de l'industrie pharmaceutique européenne au poste de président de Jaguar International

Crofelemer Expansion Commerciale Industrie Pharmaceutique Santé Jaguar Massimo Radaelli
PRESS RELEASE

published on 04/02/2024 at 14:30, 2 years 2 months ago

Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
Dr. Massimo Radaelli appointed as President of Jaguar International to expand commercial footprint globally with recent out-license agreement. Key pharmaceutical industry leader with vast experience and expertise

Pharmaceutical Industry Jaguar Health International Expansion Massimo Radaelli Out-license Agreement

Accesswire

Published on 06/26/2026 at 01:40, 10 hours 31 minutes ago

UraniumX Announces DTC Eligibility for U.S. Traded Shares
Published on 06/25/2026 at 23:30, 12 hours 41 minutes ago

Zeus North America Mining Corp. Signs Option Agreement to Acquire Mining Claims in Idaho
Published on 06/25/2026 at 22:30, 13 hours 41 minutes ago

Fountain Asset Corp. Provides Corporate Update
Published on 06/25/2026 at 21:32, 14 hours 39 minutes ago

BlackBerry Announces Election Results for the Company's Board of Directors
Published on 06/25/2026 at 15:30, 20 hours 41 minutes ago

Silver Spruce Resources, Inc. Adds Mining, Energy, and Finance Development Expertise to the Board and Announces Director Resignation

View all ACCESSWIRE

EQS Group

Published on 06/26/2026 at 11:30, 41 minutes ago

Amundi Index Solutions: NOTICE TO SHAREHOLDERS
Published on 06/26/2026 at 11:14, 56 minutes ago

EQS-Adhoc: Evonik Industries AG: Current financial and forecast data for the second quarter of 2026 and adjustment of the outlook for the financial year 2026
Published on 06/26/2026 at 11:05, 1 hour 6 minutes ago

Join the Beautiful Game: Discover Immersive Fan Experiences with Hisense at FIFA World Cup 2026™
Published on 06/26/2026 at 10:59, 1 hour 12 minutes ago

HELIOS SOLAR AG starts subscription period for Initial Public Offering – shares offered at EUR 4.00
Published on 06/26/2026 at 10:50, 1 hour 20 minutes ago

Indotek Group acquires remaining 53% stake in Auchan Hungary, assumes full ownership

Les Echos

Published on 06/26/2026 at 07:00, 5 hours 11 minutes ago

Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 5 hours 11 minutes ago

Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 18:45, 17 hours 26 minutes ago

Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 17 hours 41 minutes ago

Avis financier semestriel SIEHM au 30 avril 2026
Published on 06/25/2026 at 17:50, 18 hours 21 minutes ago

DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS

View all LES ECHOS COMFI WIRE